AbbVie falls 2.0% as healthcare sector slides after upbeat quarterly results

What happened

AbbVie (ABBV) fell 2.0% on November 2, 2026, as the healthcare sector slid, a move largely in line with peers rather than driven by fresh company-specific news. The stock opened 1.5% below the previous close, traded at 1.7 times its 20-day average volume, and closed at $288.94. Market action that day also reflected a broader pullback: the S&P 500 fell 0.5% and the healthcare sector median fell 1.6%.

How big was the move

The day’s decline was 1.6 times a typical daily move for this stock, indicating a moderately outsized session. Compared with its sector, the stock was 0.4 percentage points worse than the sector median. Over the last five sessions the stock rose 0.8% while the S&P 500 fell 1.8% over the same period, underscoring that AbbVie’s short-term strength has come amid wider market weakness.

AbbVie’s market sensitivity is low, with a beta of 0.11, meaning the stock tends to move less than the market. In the past five years the stock had 77 sessions with a decline of at least 2.0%. Twenty trading days later the median result was a gain of 2.7%, and 53 of 77 were higher. That historical record places the session in context but does not imply a particular future path.

The technical picture

The stock traded above its key moving averages: 2.2% above its 20-day moving average, 7.1% above its 50-day moving average and 21.7% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 94 consecutive trading days above the 200-day average.

The Relative Strength Index (14 days) was 62, in a neutral range between 30 and 70. The shares sat 3.3% below the 52-week high and had risen 9.9% over one month, 18.5% over three months and 26.6% over one year, outperforming the S&P 500 by 16.1 percentage points over the past year. Volatility was 20% annualized over 60 days, lower than 67% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, the company reported revenue of $66.01 billion, which grew 10.7% from a year earlier. Diluted earnings per share were $5.83, which rose 338.0% from a year earlier. Profitability strengthened markedly: gross margin widened to 76.3% from 69.7% a year earlier and operating margin improved to 35.5% from 15.2%.

Return on invested capital was 13.5%, reflecting the company’s improved operating efficiency. On valuation measures the stock trades at 49.6 times trailing earnings, higher than 52% of its own readings over the past five years; the five-year median is 48.6 times earnings. Price to forward earnings is 20.8 times expected earnings.

PromtFinance scores rank the company strongly on Quality and Stability at 100 (Exceptional) each, with Momentum 82 (Strong) and Growth 68 (Positive). Value is 63 (Neutral) and Revisions 44 (Weak), indicating well-regarded fundamentals but mixed near-term analyst sentiment.

Earnings and analyst expectations

AbbVie last reported on October 30, 2026, delivering earnings per share of $3.82 against $3.73 expected, 2.4% above estimates. That marked the seventh consecutive quarter beating estimates, with an average surprise of 2.0% above estimates over the last four reports. Typical two-day reactions after recent reports have seen the stock rose 0.2%.

Following the October report management raised its 2026 revenue and earnings outlook, citing growth from Skyrizi, Rinvoq and neuroscience, with oncology milestones also supporting prospects. Coverage remains broad: 44 analysts publish ratings, 70% of which rate the stock Buy or Strong Buy. The consensus price target is $294.00, 1.8% above the closing price.

The company’s market value stood at $521.11 billion, reflecting investor willingness to pay for improving growth and margins even as the trailing multiple is elevated. Recent reporting and guidance helped lift expectations, but the stock’s decline on November 2, 2026, showed it still moved with the sector when investors pulled back.

What to watch

• October 30, 2026: earnings per share of $3.82 against $3.73 expected, 2.4% above estimates
• February 3, 2027: next scheduled earnings report
• Revenue for the four quarters through September 30, 2026: $66.01 billion, grew 10.7% year-over-year
• Price to trailing earnings: 49.6 times; price to forward earnings: 20.8 times
• Trading volume on November 2, 2026: 1.7 times its 20-day average